NCT01710267View on ClinicalTrials.gov

Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)

CompletedOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Trial Locations (1)

6000

Luzerner Kantonsspital, Lucerne

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Research Foundation, Division of Hematology, Luzerner Kantonsspital, Switzerland

UNKNOWN

collaborator

Bayer

INDUSTRY

lead

Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD

OTHER